The results of 21-year experience of treating anal squamous cell carcinomas
Fikret İrkin1, Kaptan Gülben2, Uğur Berberoğlu2, Hüseyin Altınyollar3, Gökçe Acun5, Yıldız Güney5, Bülent Küçükpilakçı5
1Clinic of General Surgery, Private Etimed Hospital, Ankara, Turkey
2Clinic of General Surgery, Ankara Oncology Teaching and Training Hospital, Ankara, Turkey
3Clinic of General Surgery, Private Bayındır Kavaklıdere Hospital, Ankara, Turkey
4Clinic of General Surgery Kars State Hospital, Kars, Turkey
5Clinic of Radiation Oncology, Ankara Oncology Teaching and Training Hospital, Ankara, Turkey
Abstract
Objective: Anal squamous cell carcinomas are one of the rare cancer types. Due to the developments in the past35 years, surgery is no longer the first treatment of choice. The aim of this study was to retrospectively examine the outcomes of 24 patients treated in a single center in the last 21 years in terms of applied treatment, local relapse, distant metastasis, post-treatment complications, and survival.
Material and Methods: Data obtained from 24 anal squamous cell carcinoma patients, who were treated in Ankara Oncology Research and Education Hospital between 1990 and 2010, were retrospectively evaluated.
Results: Of the 24 patients, 16 had anal canal squamous cell carcinoma and eight had perianal squamous cell carcinoma. All of the patients with anal canal squamous cell carcinoma (n=16) received chemoradiotherapy. Three of these patients who did not respond to treatment, underwent abdominoperineal resection. The patients with perianal squamous cell tumors were treated by local excision. During the follow -ups, seven patients experienced local relapse, and one patient had distant organ metastasis. Only one patient died. Five-year disease free survival rate was found as 66%.
Conclusion: Our findings suggest that the first alternative in the treatment of anal squamous cell tumors should be chemoradiotherapy; and surgery seems to be the appropriate approach for the non-responsive and relapsing cases.
Keywords: Anal tumors, squamous cell carcinomas, chemoradiotherapy, abdominoperineal resection
Since it is a retrospective study, we did not apply for ethical committee approval and obtained our data from patients’ files.
Written informed consent was obtained from patient who participated in this study.
Externally peer-reviewed.
Concept - F.İ., U.B., H.A., B.K., Y.G.; Design - K.G., H.A., G.A.; Supervision - U.B., K.G., H.A., Y.G., B.K.; Data Collection and/or Processing - F.İ., H.A., G.A., B.K.; Analysis and/or Interpretation - U.B., F.İ., K.G., Y.G.; Literature Review - F.İ., G.A.; Writer - F.İ., Y.G., B.K., U.B., K.G.; Critical Review - U.B., K.G.
No conflict of interest was declared by the authors.
The authors declared that this study has received no financial support.